Biological treatments for severe asthma: where do we stand?

被引：19

作者：

Busse, William W. ^{[1
]}

机构：

[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Allergy Pulm & Crit Care Med, Madison, WI 53706 USA

来源：

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY | 2018年 / 18卷 / 06期

关键词：

asthma treatment; biologics; biomarkers; severe asthma; ALLERGIC-ASTHMA; OMALIZUMAB; BENRALIZUMAB; MEPOLIZUMAB; ANTIBODY;

D O I：

10.1097/ACI.0000000000000487

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Purpose of review For patients with severe asthma, disease control is not achieved resulting in persistent morbidity and risks for exacerbations. The advent of biologics is providing a new form of treatment for many with severe asthma. Recent findings Four mAb biologics are approved for clinical use: omalizumab (anti-IgE) and three antieosinophilic interventions (mepolizumab, reslizumab, and benralizumab). These four biologics target components of the type 2-inflammatory pathway which is reflected by biomarkers: peripheral blood eosinophils and exhaled nitric oxide. In severe asthma, biologics have reduced asthma exacerbations. The antieosinophilic biologics have also improved lung function. The safety profile of these biologics has been good. For patients with severe asthma and biomarkers indicating a type 2 inflammatory pathway, the addition of biologics has proven to be an effective approach to achieve disease control and is an appropriate next step treatment.

引用

页码：509 / 518

页数：10

共 23 条

[1] Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma [J].

Aaron, Shawn D. ;

Vandemheen, Katherine L. ;

FitzGerald, J. Mark ;

Ainslie, Martha ;

Gupta, Samir ;

Lemiere, Catherine ;

Field, Stephen K. ;

McIvor, R. Andrew ;

Hernandez, Paul ;

Mayers, Irvin ;

Mulpuru, Sunita ;

Alvarez, Gonzalo G. ;

Pakhale, Smita ;

Mallick, Ranjeeta ;

Boulet, Louis-Philippe .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (03) :269-279

[2] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].

Bel, Elisabeth H. ;

Wenzel, Sally E. ;

Thompson, Philip J. ;

Prazma, Charlene M. ;

Keene, Oliver N. ;

Yancey, Steven W. ;

Ortega, Hector G. ;

Pavord, Ian D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197

[3] Adherence and persistence with fluticasone propionate/salmeterol combination therapy [J].

Bender, Bruce G. ;

Pedan, Alex ;

Varasteh, Laleh T. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (04) :899-904

[4] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J].

Bleecker, Eugene R. ;

FitzGerald, J. Mark ;

Chanez, Pascal ;

Papi, Alberto ;

Weinstein, Steven F. ;

Barker, Peter ;

Sproule, Stephanie ;

Gilmartin, Geoffrey ;

Aurivillius, Magnus ;

Werkstrom, Viktoria ;

Goldman, Mitchell .

LANCET, 2016, 388 (10056) :2115-2127

[5] Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children [J].

Busse, William W. ;

Morgan, Wayne J. ;

Gergen, Peter J. ;

Mitchell, Herman E. ;

Gern, James E. ;

Liu, Andrew H. ;

Gruchalla, Rebecca S. ;

Kattan, Meyer ;

Teach, Stephen J. ;

Pongracic, Jacqueline A. ;

Chmiel, James F. ;

Steinbach, Suzanne F. ;

Calatroni, Agustin ;

Togias, Alkis ;

Thompson, Katherine M. ;

Szefler, Stanley J. ;

Sorkness, Christine A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (11) :1005-1015

[6] Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma [J].

Castro, M. ;

Corren, J. ;

Pavord, I. D. ;

Maspero, J. ;

Wenzel, S. ;

Rabe, K. F. ;

Busse, W. W. ;

Ford, L. ;

Sher, L. ;

FitzGerald, J. M. ;

Katelaris, C. ;

Tohda, Y. ;

Zhang, B. ;

Staudinger, H. ;

Pirozzi, G. ;

Amin, N. ;

Ruddy, M. ;

Akinlade, B. ;

Khan, A. ;

Chao, J. ;

Martincova, R. ;

Graham, N. M. H. ;

Hamilton, J. D. ;

Swanson, B. N. ;

Stahl, N. ;

Yancopoulos, G. D. ;

Teper, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) :2486-2496

[7]

Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]

[8] International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [J].

Chung, Kian Fan ;

Wenzel, Sally E. ;

Brozek, Jan L. ;

Bush, Andrew ;

Castro, Mario ;

Sterk, Peter J. ;

Adcock, Ian M. ;

Bateman, Eric D. ;

Bel, Elisabeth H. ;

Bleecker, Eugene R. ;

Boulet, Louis-Philippe ;

Brightling, Christopher ;

Chanez, Pascal ;

Dahlen, Sven-Erik ;

Djukanovic, Ratko ;

Frey, Urs ;

Gaga, Mina ;

Gibson, Peter ;

Hamid, Qutayba ;

Jajour, Nizar N. ;

Mauad, Thais ;

Sorkness, Ronald L. ;

Teague, W. Gerald .

EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (02) :343-373

[9] Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts [J].

Corren, Jonathan ;

Weinstein, Steven ;

Janka, Lindsay ;

Zangrilli, James ;

Garin, Margaret .

CHEST, 2016, 150 (04) :799-810

[10] Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction [J].

Dunican, Eleanor M. ;

Elicker, Brett M. ;

Gierada, David S. ;

Nagle, Scott K. ;

Schiebler, Mark L. ;

Newell, John D. ;

Raymond, Wilfred W. ;

Lachowicz-Scroggins, Marrah E. ;

Di Maio, Selena ;

Hoffman, Eric A. ;

Castro, Mario ;

Fain, Sean B. ;

Jarjour, Nizar N. ;

Israel, Elliot ;

Levy, Bruce D. ;

Erzurum, Serpil C. ;

Wenzel, Sally E. ;

Meyers, Deborah A. ;

Bleecker, Eugene R. ;

Phillips, Brenda R. ;

Mauger, David T. ;

Gordon, Erin D. ;

Woodruff, Prescott G. ;

Peters, Michael C. ;

Fahy, John V. .

JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (03) :997-1009

← 1 2 3 →